Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cabometyx

- PMLiVE

Bruno Strigini leaves Merck & Co for Novartis

Will head up an oncology business boosted by the acquisition of GSK's portfolio

- PMLiVE

ASCO: AZ’s ovarian cancer combination aces trial

Olaparib/cediranib combo demonstrates progression-free survival of 17.7 months

- PMLiVE

GSK and Bayer strike new biotech cancer deals

Agreements with Orion and Adaptimmune aimed at strengthening their respective oncology pipelines

- PMLiVE

Interview: AstraZeneca’s Susan Galbraith

As ASCO commences the company's VP of oncology talks to PMLiVE about its pipeline prospects in cancer

Bristol-Myers Squibb (BMS) building

BMS’ nivolumab gets breakthrough status

But shares fall on concerns over new trial data

- PMLiVE

Macmillan campaign for legacy donations

Cancer charity aims to raise awareness of the importance of gifts in wills

Bristol-Myers Squibb (BMS) building

BMS buys Alzheimer’s player iPierian in $725m deal

Takes control of several promising candidates for neurodegenerative diseases

- PMLiVE

NICE rejects Roche’s Kadcyla as “unaffordable”

Cancer drug unable to justify £90,000 price tag

Novartis building

Novartis pays $16bn for GSK’s oncology portfolio

Swiss company strikes series of deals, including one to step away from vaccines

- PMLiVE

Lilly’s stomach cancer drug cleared by FDA

Cyramza is tipped to reach blockbuster status depending on approvals

- PMLiVE

BioAlliance and Topotarget merge to focus on rare cancers

French and Danish firms combine to develop orphan oncology drugs

- PMLiVE

UK cancer awards programme launches

QiC Oncology 2014  announced at ABPI Annual Conference

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links